We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
89bio Inc
4 own
6 watching
Current Price
$17.69
$1.14
(6.89%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,289.03M
52-Week High
18.915
52-Week Low
2.75
Average Volume
1.01M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,289.03M52-Week High18.91552-Week Low2.75Average Volume1.01MDividend Yield--P/E Ratio--What does the 89bio Inc do?
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Read More
How much money does 89bio Inc make?
News & Events about 89bio Inc.
Ticker Report
1month ago
89bio, Inc. (NASDAQ:ETNB Get Rating) Director Michael R. Hayden bought 61,538 shares of the stock in a transaction that occurred on Tuesday, March 28th. The stock was acquired at an average price of $16.15 per share, for a total transaction of $993,838.70. Following the acquisition, the ...
Zolmax
2 months ago
89bio, Inc. (NASDAQ:ETNB Get Rating) Stock analysts at HC Wainwright increased their Q1 2023 EPS estimates for 89bio in a research report issued to clients and investors on Monday, March 20th. HC Wainwright analyst E. Arce now expects that the company will earn ($0.40) per share for the quarter, up ...
Globe Newswire
2 months ago
SAN FRANCISCO, March 24, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (89bio) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of its ...
Globe Newswire
2 months ago
Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 Feedback from FDA supports advancement of Phase 3 program for pegozafermin in SHTG; plan to initiate first of two SHTG Phase 3 trials in the second quarter of 2023 Published results of Phase 1b/2a study of ...
Globe Newswire
3 months ago
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data from...
Frequently Asked Questions
Frequently Asked Questions
What is 89bio Inc share price today?
Can Indians buy 89bio Inc shares?
How can I buy 89bio Inc shares from India?
Can Fractional shares of 89bio Inc be purchased?
What are the documents required to start investing in 89bio Inc stocks?
What is today’s traded volume of 89bio Inc?
What is today’s market capitalisation of 89bio Inc?
What is the 52-Week High and Low Range of 89bio Inc?
What percentage is 89bio Inc down from its 52-Week High?
What percentage is 89bio Inc up from its 52-Week Low?
Current Price
$17.69
$1.14
(6.89%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.